{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:06:46Z","timestamp":1773446806919,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ejps.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T04:51:37Z","timestamp":1465707097000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice"],"prefix":"10.1016","volume":"91","author":[{"given":"Sabine M.","family":"Poppenborg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunda","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-5265","authenticated-orcid":false,"given":"Ralf","family":"Kr\u00e4hmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Baumgart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Leenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.06.007_bb0005","first-page":"175","article-title":"Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-Asparaginase conjugates","volume":"7","author":"Abuchowski","year":"1984","journal-title":"Cancer Biochem. Biophys."},{"key":"10.1016\/j.ejps.2016.06.007_bb0010","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkh\u00e4user","first-page":"147","article-title":"The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)","author":"Armstrong","year":"2009"},{"key":"10.1016\/j.ejps.2016.06.007_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-Asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2016.06.007_bb0020","first-page":"367","article-title":"Comparative pharmacokinetic\/pharmacodynamic characterisation of a new pegylated recombinant E. coli l-Asparaginase preparation (MC0609) in Beagle dog. Cancer Chemother","volume":"74","author":"Borghorst","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejps.2016.06.007_bb0035","first-page":"99","article-title":"Antibody response to Escherichia coli l-asparaginase. Prognostic significance and clinical utility of antibody measurement","volume":"8","author":"Cheung","year":"1986","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0040","unstructured":"EMA\/CHMP\/EPAR\/Spectrila:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_- Public_assessment_report\/human\/002661\/WC500200540.pdf)"},{"key":"10.1016\/j.ejps.2016.06.007_bb0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/jpet.114.220780","article-title":"Effect of premedications in a murine model of asparaginase hypersensitivity","volume":"352","author":"Fernandez","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2016.06.007_bb0050","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejps.2016.06.007_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2016.06.007_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.taap.2014.03.002","article-title":"Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs","volume":"277","author":"Hashimoto","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2009.07923.x","article-title":"A population pharmacokinetic model for pegylated-Asparaginase in children","volume":"148","author":"Hempel","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0070","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejps.2016.06.007_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"27","author":"Ichihara","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2016.06.007_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1248\/bpb.b13-00121","article-title":"Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers","volume":"36","author":"Ishida","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2016.06.007_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2016.06.007_bb0090","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-009-9943-x","article-title":"Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles","volume":"26","author":"Ishihara","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.06.007_bb0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0169-409X(93)90005-O","article-title":"The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential","volume":"10","author":"Katre","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2016.06.007_bb0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","article-title":"Polyethylene Glycol-conjugated l-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866)","volume":"33","author":"Kurtzberg","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","article-title":"Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-Asparaginase in human serum","volume":"309","author":"Lanvers","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejps.2016.06.007_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vascn.2011.07.003","article-title":"A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers","volume":"64","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2016.06.007_bb9000","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2016.06.007_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejps.2016.06.007_bb0120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/clpt.2009.162","article-title":"Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia","volume":"86","author":"Panetta","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.06.007_bb0125","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"Pieters","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2016.06.007_bb0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.molimm.2013.07.014","article-title":"Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins","volume":"57","author":"Saifer","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejps.2016.06.007_bb0140","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.06.007_bb0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2016.06.007_bb0150","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2016.06.007_bb0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejps.2016.06.007_bb0160","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2016.06.007_bb0170","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2013.090563","article-title":"Pediatric Acute Lymphoblastic Leukemia: efficacy and safety of recombinant E. coli-Asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia","volume":"98","author":"van der Sluis","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2016.06.007_bb0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","article-title":"Questioning the use of PEGylation for drug delivery","volume":"3","author":"Verhoef","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2016.06.007_bb0180","first-page":"1","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"7","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2016.06.007_bb0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hyb.2007.006","article-title":"Generation and characterization of a monoclonal IgG antibody to polyethylene glycol","volume":"26","author":"Wunderlich","year":"2007","journal-title":"Hybridoma"},{"key":"10.1016\/j.ejps.2016.06.007_bb0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly(ethy1ene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.06.007_bb0200","first-page":"306","article-title":"Comput Methods Programs PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Biomedical"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:28:24Z","timestamp":1536636504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716302214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":37,"alternative-id":["S0928098716302214"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.06.007","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}